Companies › Shanghai Institute Of Biological Products
10 active drug programs in 11 registered trials: 10 Phase 1, 1 Phase 2; Oncology, Infectious disease, Metabolic and endocrine; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SIBP-03 HER3 monoclonal antibody | ERBB3 | Phase 2 | Head and Neck Squamous Cell Carcinoma | – |
| SIBP-A17 HER2-targeted antibody-drug conjugate (ADC) | ERBB2 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| SIBP-R002 (Peguricase for injection) Non-selective xanthine oxidase inhibitor | XDH | Phase 1 | Gout | Dec 2026 |
| Recombinant herpes zoster vaccine with low-dose adjuvant (Candidate 1) Recombinant herpes zoster vaccine with low-dose adjuvant | – | Phase 1 | Herpes Zoster (HZ) | Dec 2027 |
| SIBP-A18 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 1 | Solid Tumor Malignancy | May 2028 |
| SIBP-A19 | – | Phase 1 | Advanced Solid Tumors | Dec 2028 |
| SIBP-A10 | – | Phase 1 | Advanced Tumors | Dec 2028 |
| Influenza virus split vaccine (0.7mL/vial) Inactivated split influenza vaccine containing hemagglutinin antigens from H1N1, H3N2, and | – | Phase 1 | Influenza | – |
| MVA strain monkeypox attenuated live vaccine Attenuated live monkeypox vaccine (MVA strain) | – | Phase 1 | Monkeypox | – |
| SIBP-A13 HER3-targeting antibody-drug conjugate | ERBB3 | Phase 1 | Advanced Solid Tumor | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06771479 | MVA strain monkeypox attenuated live vaccine | Phase 1 | Monkeypox | Infectious disease | Jan 2026 |
| NCT06298058 | SIBP-A13 | Phase 1 | Advanced Solid Tumor | Oncology | Apr 2026 |
| NCT06194656 | SIBP-03 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Jul 2026 |
| NCT07302256 | Influenza virus split vaccine (0.7mL/vial) | Phase 1 | Influenza | Infectious disease | Aug 2026 |
| NCT06512116 | SIBP-A17 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT06298071 | SIBP-R002 (Peguricase for injection) | Phase 1 | Gout | Metabolic and endocrine | Dec 2026 |
| NCT06932523 | Recombinant herpes zoster vaccine with low-dose adjuvant (Candidate 1) | Phase 1 | Herpes Zoster (HZ) | Infectious disease | Dec 2027 |
| NCT06932523 | Recombinant herpes zoster vaccine with low-dose adjuvant (Candidate 1) | Phase 1 | Herpes Zoster (HZ) | Infectious disease | Dec 2027 |
| NCT06985368 | SIBP-A18 | Phase 1 | Solid Tumor Malignancy | Oncology | May 2028 |
| NCT06990464 | SIBP-A19 | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2028 |
| NCT07205198 | SIBP-A10 | Phase 1 | Advanced Tumors | Oncology | Dec 2028 |
DualityBio Shenyang Sunshine Pharmaceutical SystImmune BioRay Pharmaceutical Alentis Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.